Novel method based on "en passant" mutagenesis coupled with a gaussia luciferase reporter assay for studying the combined effects of human cytomegalovirus mutations

Journal of Clinical Microbiology

Volumn 51, Issue 10, 2013, Pages 3216-3224

  Drouot, Emilien ^a   Piret, Jocelyne ^a   Boivin, Guy ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; FOSCARNET; GANCICLOVIR; GAUSSIA LUCIFERASE; LUCIFERASE; UNCLASSIFIED DRUG;

ANTIVIRAL SUSCEPTIBILITY; ARTICLE; ASSAY; BACTERIAL ARTIFICIAL CHROMOSOME; CELL CULTURE; CONTROLLED STUDY; EN PASSANT MUTAGENESIS; ENZYME ACTIVITY; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; MOLECULAR CLONING; MUTAGENESIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REPORTER GENE; VALIDITY; VIRUS GENOME;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; DNA, VIRAL; GENES, REPORTER; HUMANS; LUCIFERASES; MICROBIAL SENSITIVITY TESTS; MUTAGENESIS; MUTATION;

EID: 84884806690     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01275-13     Document Type: Article

References (40)

1. Bate SL, Dollard SC, Cannon MJ. 2010. Cytomegalovirus seroprevalence in the United States: the National Health and Nutrition Examination Surveys, 1988-2004. Clin. Infect. Dis. 50:1439-1447.
2. Cannon MJ, Schmid DS, Hyde TB. 2010. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev. Med. Virol. 20:202-213.
3. Steininger C. 2007. Clinical relevance of cytomegalovirus infection in patients with disorders of the immune system. Clin. Microbiol. Infect. 13:953-963. (Pubitemid 47382250)
4. Streblow DN, Orloff SL, Nelson JA. 2007. Acceleration of allograft failure by cytomegalovirus. Curr. Opin. Immunol. 19:577-582. (Pubitemid 47464920)
5. Gilbert C, Boivin G. 2005. Human cytomegalovirus resistance to antiviral drugs. Antimicrob. Agents Chemother. 49:873-883. (Pubitemid 40327699)
6. Biron KK, Stanat SC, Sorrell JB, Fyfe JA, Keller PM, Lambe CU, Nelson DJ. 1985. Metabolic activation of the nucleoside analog 9-([2-hydroxy-1- (hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc. Natl. Acad. Sci. U. S. A. 82: 2473-2477. (Pubitemid 15071291)
7. Cihlar T, Chen MS. 1996. Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells. Mol. Pharmacol. 50:1502-1510. (Pubitemid 26425105)
8. Sullivan V, Talarico CL, Stanat SC, Davis M, Coen DM, Biron KK. 1992. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 358:162-164.
9. Oberg B. 1989. Antiviral effects of phosphonoformate (PFA, foscarnet sodium). Pharmacol. Ther. 40:213-285. (Pubitemid 19011100)
10. Lurain NS, Chou S. 2010. Antiviral drug resistance of human cytomegalovirus. Clin. Microbiol. Rev. 23:689-712.
11. Erice A, Chou S, Biron KK, Stanat SC, Balfour HH, Jr, Jordan MC. 1989. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N. Engl. J. Med. 320:289-293. (Pubitemid 19045553)
12. Fillet AM, Auray L, Alain S, Gourlain K, Imbert BM, Najioullah F, Champier G, Gouarin S, Carquin J, Houhou N, Garrigue I, Ducancelle A, Thouvenot D, Mazeron MC. 2004. Natural polymorphism of cytomegalovirus DNA polymerase lies in two nonconserved regions located between domains delta-C and II and between domains III and I. Antimicrob. Agents Chemother. 48:1865-1868. (Pubitemid 38544399)
13. Chou S, Lurain NS, Weinberg A, Cai GY, Sharma PL, Crumpacker CS. 1999. Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance: Adult AIDS Clinical Trials Group CMV Laboratories. Antimicrob. Agents Chemother. 43:1500-1502. (Pubitemid 29259354)
14. Landry ML, Stanat S, Biron K, Brambilla D, Britt W, Jokela J, Chou S, Drew WL, Erice A, Gilliam B, Lurain N, Manischewitz J, Miner R, Nokta M, Reichelderfer P, Spector S, Weinberg A, Yen-Lieberman B, Crumpacker C. 2000. A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates. Antimicrob. Agents Chemother. 44:688-692. (Pubitemid 30117962)
15. Chou S, Van Wechel LC, Lichy HM, Marousek GI. 2005. Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene. Antimicrob. Agents Chemother. 49: 2710-2715. (Pubitemid 40917582)
16. Cihlar T, Fuller MD, Cherrington JM. 1998. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. J. Virol. 72:5927-5936. (Pubitemid 28283381)
17. Martin M, Gilbert C, Covington E, Boivin G. 2006. Characterization of human cytomegalovirus (HCMV) UL97 mutations found in a valganciclovir/oral ganciclovir prophylactic trial by use of a bacterial artificial chromosome containing the HCMV genome. J. Infect. Dis. 194:579-583. (Pubitemid 44297841)
18. Chou S. 2010. Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. Antimicrob. Agents Chemother. 54:2371-2378.
19. Sinzger C, Hahn G, Digel M, Katona R, Sampaio KL, Messerle M, Hengel H, Koszinowski U, Brune W, Adler B. 2008. Cloning and sequencing of a highly productive, endotheliotropic virus strain derived from human cytomegalovirus TB40/E. J. Gen. Virol. 89:359-368. (Pubitemid 351622433)
20. Warming S, Costantino N, Court DL, Jenkins NA, Copeland NG. 2005. Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res. 33:e36.
21. Wang S, Zhao Y, Leiby M, Zhu J. 2009. A new positive/negative selection scheme for precise BAC recombineering. Mol. Biotechnol. 42:110-116.
22. Tischer BK, von Einem J, Kaufer B, Osterrieder N. 2006. Two-step red-mediated recombination for versatile high-efficiency markerless DNA manipulation in Escherichia coli. Biotechniques 40:191-197. (Pubitemid 46542640)
23. He R, Sandford G, Hayward GS, Burns WH, Posner GH, Forman M, Arav-Boger R. 2011. Recombinant luciferase-expressing human cytomegalovirus (CMV) for evaluation of CMV inhibitors. Virol. J. 8:40.
24. Marschall M, Freitag M, Weiler S, Sorg G, Stamminger T. 2000. Recombinant green fluorescent protein-expressing human cytomegalovirus as a tool for screening antiviral agents. Antimicrob. Agents Chemother. 44:1588-1597. (Pubitemid 30340800)
25. Dal Pozzo F, Andrei G, Daelemans D, Winkler M, Piette J, De Clercq E, Snoeck R. 2008. Fluorescence-based antiviral assay for the evaluation of compounds against vaccinia virus, varicella zoster virus and human cytomegalovirus. J. Virol. Methods 151:66-73.
26. Chevillotte M, Schubert A, Mertens T, von Einem J. 2009. Fluorescencebased assay for phenotypic characterization of human cytomegalovirus polymerase mutations regarding drug susceptibility and viral replicative fitness. Antimicrob. Agents Chemother. 53:3752-3761.
27. Tannous BA. 2009. Gaussia luciferase reporter assay for monitoring biological processes in culture and in vivo. Nat. Protoc. 4:582-591.
28. Bresnahan WA, Hultman GE, Shenk T. 2000. Replication of wild-type and mutant human cytomegalovirus in life-extended human diploid fibroblasts. J. Virol. 74:10816-10818.
29. Kollert-Jons A, Bogner E, Radsak K. 1991. A 15-kilobase-pair region of the human cytomegalovirus genome which includes US1 through US13 is dispensable for growth in cell culture. J. Virol. 65:5184-5189.
30. Baldick CJ, Jr, Marchini A, Patterson CE, Shenk T. 1997. Human cytomegalovirus tegument protein pp71 (ppUL82) enhances the infectivity of viral DNA and accelerates the infectious cycle. J. Virol. 71:4400-4408. (Pubitemid 27204129)
31. Colleaux L, d'Auriol L, Betermier M, Cottarel G, Jacquier A, Galibert F, Dujon B. 1986. Universal code equivalent of a yeast mitochondrial intron reading frame is expressed into E. coli as a specific double strand endonuclease. Cell 44:521-533.
32. Tischer BK, Smith GA, Osterrieder N. 2010. En passant mutagenesis: a two step markerless red recombination system. Methods Mol. Biol. 634: 421-430.
33. Sharan SK, Thomason LC, Kuznetsov SG, Court DL. 2009. Recombineering: a homologous recombination-based method of genetic engineering. Nat. Protoc. 4:206-223.
34. Jones TR, Muzithras VP. 1992. A cluster of dispensable genes within the human cytomegalovirus genome short component: IRS1, US1 through US5, and the US6 family. J. Virol. 66:2541-2546.
35. Borst EM, Hahn G, Koszinowski UH, Messerle M. 1999. Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J. Virol. 73:8320-8329. (Pubitemid 29441693)
36. Tannous BA, Kim DE, Fernandez JL, Weissleder R, Breakefield XO. 2005. Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. Mol. Ther. 11:435-443. (Pubitemid 40277320)
37. Hakki M, Drummond C, Houser B, Marousek G, Chou S. 2011. Resistance to maribavir is associated with the exclusion of pUL27 from nucleoli during human cytomegalovirus infection. Antiviral Res. 92:313-318.
38. Schreiber A, Harter G, Schubert A, Bunjes D, Mertens T, Michel D. 2009. Antiviral treatment of cytomegalovirus infection and resistant strains. Expert Opin. Pharmacother. 10:191-209.
39. Chevillotte M, von Einem J, Meier BM, Lin FM, Kestler HA, Mertens T. 2010. A new tool linking human cytomegalovirus drug resistance mutations to resistance phenotypes. Antiviral Res. 85:318-327.
40. Lischka P, Hewlett G, Wunberg T, Baumeister J, Paulsen D, Goldner T, Ruebsamen-Schaeff H, Zimmermann H. 2010. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob. Agents Chemother. 54:1290-1297.